Testing Pasritamig Before Surgery for the Treatment of Localized Prostate Cancer

Part of paid clinical trials in Seattle, Washington.

Sponsor
Fred Hutchinson Cancer Center
Study ID
NCT07860255
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
MALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This phase I trial tests the safety and feasibility of giving pasritamig before surgery in patients with unfavorable intermediate-risk, high-risk, or very high-risk localized prostate cancer. Pasritamig is a bispecific antibody that works by bringing immune cells called T cells close to prostate cancer cells that express KLK2, which may help the immune system attack the cancer. Giving pasritamig before radical prostatectomy may help researchers determine how the drug affects prostate cancer and the immune cells within the tumor.

Key Dates

First listed
Oct 6, 2026
Start date
Nov 30, 2026
Status verified
Oct 2026
Primary completion
Nov 30, 2028
Completion
Nov 30, 2028

Study Design

Enrollment
18 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Neoadjuvant Pasritamig
    Participants receive pasritamig IV on days 1, 8, 15, and 57. Participants then undergo standard of care radical prostatectomy. Participants also undergo blood and tissue sample collection on study.

Primary Outcome Measure

Feasibility of neoadjuvant pasritamig [ Time Frame: From first dose through radical prostatectomy, approximately 70 days ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Fred Hutch/University of Washington Cancer ConsortiumSeattleWashington98109
Fred Hutch Immunotherapy Intake
[email protected]
206-606-4668
Steven Blinka, MD, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Seattle, WA

Nationwide
Prostate cancer trialsOncology trialsProstate oncology trialsMen's health trialsUrology trials
By condition
Prostate cancer
By specialty
OncologyProstate oncologyMen's healthUrology
By research site
Fred Hutch/University of Washington Cancer Consortium· Seattle, WA

Related Studies